1. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study.
- Author
-
Salami, Simpa, Tosoian, Jeffrey, Nallandhighal, Srinivas, Jones, Tonye, Brockman, Scott, Elkhoury, Fuad, Bazzi, Selena, Plouffe, Komal, Siddiqui, Javed, Liu, Chia-Jen, Kunju, Lakshmi, Morgan, Todd, Natarajan, Shyam, Boonstra, Philip, Sumida, Lauren, Tomlins, Scott, Udager, Aaron, Sisk, Anthony, Marks, Leonard, and Palapattu, Ganesh
- Subjects
Cancer progression ,Gene fusions ,Immunohistochemistry ,Low-grade cancer ,Next-generation sequencing ,Prostate cancer ,Tumor clonality ,Cohort Studies ,Humans ,Image-Guided Biopsy ,Longitudinal Studies ,Male ,Middle Aged ,Neoplasm Grading ,Prostate ,Prostatic Neoplasms - Abstract
BACKGROUND: The potential for low-grade (grade group 1 [GG1]) prostate cancer (PCa) to progress to high-grade disease remains unclear. OBJECTIVE: To interrogate the molecular and biological features of low-grade PCa serially over time. DESIGN, SETTING, AND PARTICIPANTS: Nested longitudinal cohort study in an academic active surveillance (AS) program. Men were on AS for GG1 PCa from 2012 to 2017. INTERVENTION: Electronic tracking and resampling of PCa using magnetic resonance imaging/ultrasound fusion biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: ERG immunohistochemistry (IHC) and targeted DNA/RNA next-generation sequencing were performed on initial and repeat biopsies. Tumor clonality was assessed. Molecular data were compared between men who upgraded and those who did not upgrade to GG ≥ 2 cancer. RESULTS AND LIMITATIONS: Sixty-six men with median age 64 yr (interquartile range [IQR], 59-69) and prostate-specific antigen 4.9 ng/mL (IQR, 3.3-6.4) underwent repeat sampling of a tracked tumor focus (median interval, 11 mo; IQR, 6-13). IHC-based ERG fusion status was concordant at initial and repeat biopsies in 63 men (95% vs expected 50%, p
- Published
- 2021